Literature DB >> 2442506

Central hemodynamic changes of calcium antagonists at rest and during exercise in essential hypertension.

P Lund-Johansen, P Omvik.   

Abstract

Since the cardinal hemodynamic disorder in essential hypertension is an increased total peripheral resistance, drugs that can lower resistance without reducing blood flow would be particularly useful. The calcium antagonists seem to fulfill this criterion. The purpose of this work was to study the hemodynamic effects at rest and during exercise of three calcium channel blockers, verapamil, nifedipine, and nisoldipine, in patients with mild to moderate essential hypertension. Fifty-four patients aged 20-64 years with pretreatment diastolic blood pressures of between 95 and 120 mm Hg were studied at rest and during exercise on an ergometer bicycle. Blood pressure was recorded intraarterially and cardiac output was measured by Cardiogreen. After the initial study, 10 patients were treated with verapamil (40-80 mg three times daily), 15 with nifedipine (long-acting form, 20-80 mg daily), and 19 with nisoldipine (10-40 mg daily). After 1 year the hemodynamic study was repeated. The immediate response to the first dose was studied in the patients taking nisoldipine and in 10 patients after taking placebo tablets. Placebo induced no significant changes in central hemodynamics during the first 3 h after tablet intake. The calcium antagonists induced a reduction in blood pressure and in total peripheral resistance (in the order of 10-18%) without any reduction in cardiac index. Reflex tachycardia and an increase in cardiac output were seen in the first 2 h after the first dose of nisoldipine, but after 1 year the heart rate was unchanged compared with the pretreatment rate at rest and during exercise. In contrast, heart rate was reduced on verapamil treatment, particularly during exercise (about 10% of patients), but this was compensated for by an increase in the stroke volume. The hemodynamic profiles of the three calcium channel blockers were slightly different, especially with respect to the heart rate response. Total peripheral resistance was reduced, acutely as well as chronically, and no depression in cardiac pump function was seen, either at rest or during exercise.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442506     DOI: 10.1097/00005344-198710001-00026

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

Review 1.  Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

Authors:  M Ruzicka; F H Leenen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring.

Authors:  L Corea; M Bentivoglio; S Berioli; C Bianchini; K Savino; M Sardina
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

3.  An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease.

Authors:  B Silke; E Goldhammer; S K Sharma; S P Verma; S H Taylor
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 4.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.